Invitae IPO
Invitae is a medical genetics company that provides genetic testing services for hereditary disorders, cancer predisposition, and other genetic conditions. The company aims to make genetic testing more accessible and affordable for patients and healthcare providers. Invitae offers comprehensive genetic testing panels and genetic counseling services to support clinical decision-making.
What We Know
Invitae went public in February 2015, trading on NYSE under the ticker symbol NVTA. The company's IPO raised approximately $45 million at $7 per share. Since going public, Invitae has grown significantly through acquisitions and expansion of its testing menu, becoming one of the larger players in the genetic testing market. As a public company, Invitae has focused on scaling its operations and reducing the cost of genetic testing while expanding its reach to more patients and healthcare providers. The company has made numerous acquisitions to expand its capabilities and has worked to build a comprehensive platform for genetic testing and data analysis.
Frequently Asked Questions
Has Invitae had an IPO?
Yes, Invitae has been a public company since February 2015. The company went public on NYSE under the ticker symbol NVTA.
When is the Invitae IPO date?
Invitae completed its IPO in February 2015, raising approximately $45 million at $7 per share. The company has been publicly traded for nearly a decade.
How can I buy Invitae stock?
You can buy Invitae stock through any brokerage account as it trades publicly on NYSE under the ticker symbol NVTA. The stock is available through standard online and traditional brokerage services.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts